Literature DB >> 2112651

Nortriptyline absorption in short bowel syndrome.

J E Broyles1, R O Brown, T H Self, R C Frederick, R W Luther.   

Abstract

Severe short bowel syndrome usually requires a period of parenteral nutrition support until gastrointestinal hypertrophy occurs. Because of the shortened length of the gastrointestinal tract, oral drug therapy can be compromised secondary to decreased absorption. In the case presented, a patient with short bowel syndrome who required parenteral nutrition was able to achieve therapeutic nortriptyline serum concentrations while receiving the drug via the oral route.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112651     DOI: 10.1177/0148607190014003326

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  5 in total

1.  Systematic review of drug bioavailability following gastrointestinal surgery.

Authors:  Manuela Moreno Santamaría; José Javier Arenas Villafranca; Jimena Abilés; Alberto Fernández López; Lucia Visiedo Rodas; Begoña Tortajada Goitia; Pilar Utrilla Navarro
Journal:  Eur J Clin Pharmacol       Date:  2018-08-22       Impact factor: 2.953

Review 2.  Enteral drug absorption in patients with short small bowel : a review.

Authors:  René Severijnen; Nazila Bayat; Hans Bakker; Jules Tolboom; Ger Bongaerts
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Managing intestinal failure in inflammatory bowel disease - 'when the drugs don't work'.

Authors:  James Morgan; Ashley Bond; Cecil Kullu; Sreedhar Subramanian; Martyn Dibb; Philip J Smith
Journal:  Frontline Gastroenterol       Date:  2020-06-19

Review 4.  Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications.

Authors:  P O Gubbins; K E Bertch
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 5.  The impact of intestinal failure on oral drug absorption: a review.

Authors:  Nicola Ward
Journal:  J Gastrointest Surg       Date:  2010-01-22       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.